About Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). The company's lead candidate is ARB-1467, which is in a Phase II trial to block production of HBV surface antigen expression in patients chronically infected with HBV. Its product candidates also include AB-423, a core protein inhibitor in Phase I clinical trial as an oral therapeutic for the treatment of chronic HBV infection; and AB-452, an HBV RNA Destabilizer, which is in preclinical study. In addition, the company has various research programs for the discovery and development of proprietary HBV candidates comprising N-Acetylgalactosamine conjugate technology, cccDNA targeting agents, and checkpoint inhibition. Further, its partnered programs consist of Patisiran (ALN-TTR02), an RNAi therapeutic targeting transthyretin (TTR) that has been completed Phase III clinical trial for the treatment of TTR-mediated amyloidosis in patients with FAP; Marqibo for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy; and RNA-based neoantigen immunotherapy products. The company has strategic alliance, licensing, and research collaboration agreements with Acuitas Therapeutics Inc.; Spectrum Pharmaceuticals, Inc.; Marina Biotech Inc.; U.S. National Institutes of Health; and The Baruch S. Blumberg Institute and Drexel University. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ABUS
CUSIPN/A
Phone604-419-3200
Debt
Debt-to-Equity Ratio0.09%
Current Ratio8.85%
Quick Ratio8.85%
Price-To-Earnings
Trailing P/E Ratio-3.04
Forward P/E Ratio-3.21
P/E GrowthN/A
Sales & Book Value
Annual Sales$10.70 million
Price / Sales28.05
Cash FlowN/A
Price / CashN/A
Book Value$2.41 per share
Price / Book2.26
Profitability
EPS (Most Recent Fiscal Year)($1.79)
Net Income$-84,410,000.00
Net Margins-796.23%
Return on Equity-55.28%
Return on Assets-36.75%
Miscellaneous
Employees130
Outstanding Shares55,070,000
Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions
What is Arbutus Biopharma's stock symbol?
Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma's earnings last quarter?
Arbutus Biopharma (NASDAQ:ABUS) posted its quarterly earnings data on Wednesday, March, 14th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.51. The biopharmaceutical company had revenue of $2.50 million for the quarter, compared to analysts' expectations of $0.70 million. Arbutus Biopharma had a negative net margin of 796.23% and a negative return on equity of 55.28%. View Arbutus Biopharma's Earnings History.
When is Arbutus Biopharma's next earnings date?
What price target have analysts set for ABUS?
6 brokerages have issued twelve-month target prices for Arbutus Biopharma's shares. Their predictions range from $5.00 to $32.00. On average, they anticipate Arbutus Biopharma's share price to reach $12.3750 in the next twelve months. View Analyst Ratings for Arbutus Biopharma.
Who are some of Arbutus Biopharma's key competitors?
Some companies that are related to Arbutus Biopharma include Geron (GERN), Clementia Pharmaceuticals (CMTA), Odonate Therapeutics (ODT), Achaogen (AKAO), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Five Prime Therapeutics (FPRX), Kura Oncology (KURA), TiGenix - American Depositary Shares (TIG), Aclaris Therapeutics (ACRS), ChemoCentryx (CCXI), Dicerna Pharmaceuticals (DRNA), Akebia Therapeutics (AKBA), StemlineTherapeutics (STML), Insys Therapeutics (INSY), Progenics Pharmaceuticals (PGNX), Achillion Pharmaceuticals (ACHN) and ObsEva (OBSV).
Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the folowing people:
- Dr. Mark Joseph Murray, Chief Exec. Officer, Pres and Exec. Director (Age 69)
- Dr. Peter Lutwyche Ph.D., Chief Technology Officer (Age 52)
- Dr. Michael J. Sofia Ph.D., Chief Scientific Officer (Age 60)
- Dr. Elizabeth Howard Ph.D., J.D., Exec. VP & Gen. Counsel (Age 64)
- Mr. Koert VandenEnden C.A., CPA, Interim CFO & VP of Fin.
Has Arbutus Biopharma been receiving favorable news coverage?
News stories about ABUS stock have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a news impact score of 0.21 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.72 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Arbutus Biopharma?
Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arbutus Biopharma's stock price today?
One share of ABUS stock can currently be purchased for approximately $5.45.
How big of a company is Arbutus Biopharma?
Arbutus Biopharma has a market capitalization of $297.38 million and generates $10.70 million in revenue each year. The biopharmaceutical company earns $-84,410,000.00 in net income (profit) each year or ($1.79) on an earnings per share basis. Arbutus Biopharma employs 130 workers across the globe.
How can I contact Arbutus Biopharma?
Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]
MarketBeat Community Rating for Arbutus Biopharma (ABUS)
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Arbutus Biopharma (NASDAQ:ABUS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Arbutus Biopharma in the last 12 months. Their average twelve-month price target is $12.3750, suggesting that the stock has a possible upside of 127.06%. The high price target for ABUS is $32.00 and the low price target for ABUS is $5.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.67 | 2.67 | 2.83 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.3750 | $12.3750 | $12.50 | $15.00 |
| Price Target Upside: | 127.06% upside | 135.71% upside | 140.38% upside | 98.68% upside |
Arbutus Biopharma (NASDAQ:ABUS) Consensus Price Target History
Arbutus Biopharma (NASDAQ:ABUS) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Arbutus Biopharma (NASDAQ:ABUS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Arbutus Biopharma (NASDAQ ABUS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 62.12%
Arbutus Biopharma (NASDAQ ABUS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/3/2017 | Michael J Sofia | Insider | Sell | 10,000 | $8.00 | $80,000.00 | |  |
| 8/15/2017 | Michael J Sofia | Insider | Sell | 30,000 | $3.70 | $111,000.00 | 1,563,403 | |
| 8/24/2015 | Richard C Henriques Jr | Director | Buy | 1,000 | $6.95 | $6,950.00 | 1,000 | |
(Data available from 1/1/2013 forward)
Arbutus Biopharma (NASDAQ ABUS) News Headlines
| Source: |
|
Arbutus Biopharma (NASDAQ:ABUS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Arbutus Biopharma (NASDAQ:ABUS) Income Statement, Balance Sheet and Cash Flow Statement
Arbutus Biopharma (NASDAQ ABUS) Stock Chart for Saturday, April, 21, 2018
Loading chart…
